Pfizer’s Q2 Earnings Surge 25%, Despite Lower Lipitor Sales (PFE)

By
A A A
Share |

Drug maker Pfizer Inc. ( PFE ) on Tuesday posted better-than-expected second quarter earnings results, despite a continued slump in Lipitor cholesterol drug sales amid new generic competition.

The New York-based company reported second quarter net income of $3.25 billion, or 43 cents per share, compared with $2.61 billion, or 33 cents per share, in the year-ago period. Excluding special items, adjusted profit was 62 cents per share.

Revenue fell 8.7% from last year to $15.06 billion.

On average, Wall Street analysts expected a much smaller profit of 54 cents per share, on lower revenue of $14.87 billion.

Pfizer shares rose 27 cents, or +1.1%, in premarket trading Tuesday.

The Bottom Line
We have been recommending shares of Pfizer ( PFE ) since Mar.2, when the stock was trading at $21.49. The company has a 3.71% dividend yield, based on last night's closing stock price of $23.71.

Pfizer Inc. ( PFE ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.

Be sure to visit our complete recommended list of the Best Dividend Stocks , as well as a detailed explanation of our ratings system here .



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Created by Dividend.com


This article appears in: Investing , Stocks

Referenced Stocks: PFE

Dividend.com

Dividend.com

More from Dividend.com:

Related Videos

Stocks

Referenced

91%

Most Active by Volume

89,970,926
  • $16.15 ▲ 0.12%
77,131,582
  • $58.94 ▼ 1.31%
67,336,935
  • $26.56 ▲ 1.68%
48,814,124
  • $86.20 ▲ 0.02%
47,526,126
  • $23.21 ▲ 0.78%
44,660,424
  • $23.91 ▲ 6.36%
38,799,699
  • $4.289 ▲ 4.36%
36,199,890
  • $40.01 ▼ 0.97%
As of 4/17/2014, 04:07 PM